Regeneron: FDA approves Libtayo in combination with platinum-based chemotherapy

Regeneron Pharmaceuticals announced that the U.S. FDA has approved the PD-1 inhibitor Libtayo in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer with no EGFR, ALK or ROS1 aberrations. Patients must either have metastatic or locally advanced tumors that are not candidates for surgical resection or definitive chemoradiation. Patients may be treated with this combination irrespective of PD-L1 expression or histology.